Stock PMN PROMIS NEUROSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News ProMIS Neurosciences, Inc.

Equities

PMN

CA74346M4065

Delayed Nasdaq
Other stock markets
 11:21:15 2024-05-31 EDT 		5-day change 1st Jan Change
1.69 USD -0.88% Intraday chart for ProMIS Neurosciences, Inc. -3.18% +46.91%
05-15 ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-30 ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
AQ
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
AQ
ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
CI
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
AQ
ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS
CI
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
AQ
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April 
AQ
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
AQ
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ProMIS Neurosciences : Corporate Overview
PU
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
AQ
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
AQ
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
AQ
ProMIS Neurosciences Issues Letter to Shareholders
AQ
ProMIS Neurosciences, Inc. Announces Management Changes
CI
ProMIS Neurosciences, Inc. Announces CEO Changes
CI
ProMIS Neurosciences, Inc. Announces Leadership Transition
AQ
ProMIS Neurosciences Announces Publication on Novel Target for ALS
AQ
ProMIS Neurosciences Announces Publication on Novel Target for ALS
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PMN Stock
  4. News ProMIS Neurosciences, Inc.